Literature DB >> 9734942

Anti-inflammatory cytokine profile and mortality in febrile patients.

J T van Dissel1, P van Langevelde, R G Westendorp, K Kwappenberg, M Frölich.   

Abstract

BACKGROUND: An anti-inflammatory cytokine profile on whole-blood stimulation in vitro is associated with fatal outcome of meningococcal disease. We investigated whether an anti-inflammatory cytokine profile in the circulation is associated with adverse outcome in other infectious diseases.
METHODS: We enrolled 464 consecutive patients (272 men, 192 women) who presented to hospital with fever (> or = 38.2 degrees C). On admission we measured plasma interleukin 10 (IL-10) and tumour necrosis factor alpha (TNF alpha), and collected clinical and microbiological data on the febrile illness, then followed up all patients for clinical outcome.
FINDINGS: In at least 399 of the 464 patients fever was caused by infection. 33 patients died after a median hospital stay of 11 days (interquartile range 3-20). Concentrations of IL-10 were significantly higher in non-survivors (median 169 pg/mL [IQR 83-530]) than in survivors (median 88 pg/mL [42-235], p=0.042). When dichotomised around the median, the mortality risk was two times higher in patients who had high concentrations of IL-10 than in those with low concentrations (relative risk 2.39 [95% CI 1.07-5.33]), in patients with low and high concentrations of TNF alpha. In the 406 patients without haemodynamic deterioration in the first 24 h, IL-10 was higher and TNF alpha lower in patients who died than in those who survived. The ratio of IL-10 to TNF alpha was higher in non-survivors (median 6.9 [3.0-21.0]) than in survivors (median 3.9 [2.0-7.0], p=0.040). This ratio was highest in patients who died without underlying disease (median 21.5 [5.0-25.0]). Age, sex, and duration of fever before admission did not explain the differences in IL-10 and TNF alpha.
INTERPRETATION: An anti-inflammatory cytokine profile of a high ratio of IL-10 to TNF alpha is associated with fatal outcome in febrile patients with community-acquired infection. Our findings caution against a widespread use of proinflammatory cytokine inhibition in patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9734942     DOI: 10.1016/S0140-6736(05)60606-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  102 in total

Review 1.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Hemofiltration in septic patients is not able to alter the plasma concentration of cytokines therapeutically.

Authors:  M van Deuren; J W van der Meer
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

Review 3.  Diagnostic markers of infection in neonates.

Authors:  P C Ng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-05       Impact factor: 5.747

Review 4.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

5.  Evaluation of IL-6, CRP and hs-CRP as Early Markers of Neonatal Sepsis.

Authors:  Purushothaman Ganesan; Priyadarshini Shanmugam; Shameem Banu Abdul Sattar; Shenbaga Lalitha Shankar
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 6.  Challenges with Diagnosing and Managing Sepsis in Older Adults.

Authors:  Kalin M Clifford; Eliza A Dy-Boarman; Krystal K Haase; Kristen Maxvill; Steven E Pass; Carlos A Alvarez
Journal:  Expert Rev Anti Infect Ther       Date:  2016-01-14       Impact factor: 5.091

7.  Elevation in interleukin 13 levels in patients diagnosed with systemic inflammatory response syndrome.

Authors:  Luis A Socha; John Gowardman; Diego Silva; Manuel Correcha; Nikolai Petrosky
Journal:  Intensive Care Med       Date:  2006-01-26       Impact factor: 17.440

8.  Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis.

Authors:  L Armstrong; A R L Medford; K J Hunter; K M Uppington; A B Millar
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 9.  The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients.

Authors:  Nicholas S Ward; Brian Casserly; Alfred Ayala
Journal:  Clin Chest Med       Date:  2008-12       Impact factor: 2.878

Review 10.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.